Liquidia Corporation

Liquidia Corporation is the pulmonary-hypertension specialist whose thesis has been about Yutrepia (inhaled treprostinil) taking share from established PAH treatments. The setup is a specific product acceleration with the competitive overhang recently cleared.

• The tape has done extraordinary work — up about 131% year-to-date and 447% over twelve months at a $7.1B market cap; that shape reflects the specific product-share-take story landing on the P&L.
• The specific bull anchor is the product data — Yutrepia scripts are ramping faster than INSM and UTHR competitor products, and the community targets 'new highs next week'; CEO Roger Jeffs's credibility is a specific reason the sell-side has continued to raise numbers.
• The specific overhang release is dated — the TPIP overhang lifted after competitor data showed only 21% of patients achieved the target 640ug dose, which reinforces Yutrepia as standard of care for the PAH indication; that is a real de-risking event.
• The mechanics reflect the story-multiple math — trailing P/E of about 244 on a recovering earnings base, gross margin above 91%, operating margin near 15.8%, ROIC of 12.8%, free-cash-flow yield about 0.75%, and debt-to-equity of 1.70; the multiple prices continued script growth.
• The insider-sale signal is fair to acknowledge but limited — recent selling has been almost entirely pre-planned Rule 10b5-1 stock-option-vesting flow (~100k shares in the low $71s), which is not fundamental exit selling.

The trend stays intact as long as the next earnings shows Yutrepia script growth continuing and no safety-related disclosure — a beat with reaffirmed FY revenue guide extends the run; a specific competitive-mix or reimbursement disclosure is the plausible interruption.